<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849443</url>
  </required_header>
  <id_info>
    <org_study_id>17081704-IRB01</org_study_id>
    <nct_id>NCT03849443</nct_id>
  </id_info>
  <brief_title>Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery</brief_title>
  <official_title>Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and&#xD;
      method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim&#xD;
      of the study is to determine whether or not repeated dosing of oral or different method of&#xD;
      delivery like intravenous (IV) TXA reduces the postoperative reduction in hemoglobin,&#xD;
      hematocrit, number of transfusions, and postoperative blood loss following open spine&#xD;
      surgery. The regimen that utilizes multiple doses of oral TXA will significantly minimize&#xD;
      post-operative blood loss and transfusion requirements compared to the use of a single dose&#xD;
      regimen. Furthermore, oral TXA will be as efficacious as intravenous delivery of TXA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background/Scientific review:&#xD;
&#xD;
      Open lumbar spine surgery is associated with the risk of moderate to significant blood loss.&#xD;
      Because TXA has been shown to significantly reduce the need for blood products during total&#xD;
      joint replacement, it is now the standard of care for these procedures at many&#xD;
      institutions.1-3 Oral and IV TXA have been found to be similarly efficacious in total joint&#xD;
      replacements, but oral TXA is cheaper and allows for ease of repeat dosing.1 Although low&#xD;
      preoperative hemoglobin is a risk factor for transfusion, no studies that have compared&#xD;
      standard single-dose oral or IV TXA dosing to repeated oral dosing of TXA in patients&#xD;
      undergoing open spine surgery.&#xD;
&#xD;
      Study Design: Prospective, randomized, double-blinded study Inclusion Criteria: Any patient&#xD;
      older than 18 years old and scheduled for an open posterior thoracolumbar spinal fusion&#xD;
      procedure&#xD;
&#xD;
      Exclusion Criteria: Allergy to TXA, acquired disturbances of color vision, refusal of blood&#xD;
      products, pre-op use of anticoagulant therapy within five days before surgery, a history of&#xD;
      arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA), pregnancy,&#xD;
      breastfeeding, major comorbidities (such as severe ischemic heart disease [New York Heart&#xD;
      Association Class III or IV], previous myocardial infarction, severe pulmonary disease, renal&#xD;
      impairment, or hepatic failure), patients who decline to participate, intolerance or&#xD;
      sensitivity to Vitamin C.&#xD;
&#xD;
      Screening Procedures and Randomization: At the pre-operative clinic appointment and before&#xD;
      the day of surgery, the study staff will assess the potential subject's eligibility, which&#xD;
      would include asking for any intolerance/sensitivity to Vitamin C. Once eligibility is&#xD;
      established, the potential subject will be approached regarding their participation in this&#xD;
      clinical trial. The investigators will provide 48 hours before the date of surgery to allot&#xD;
      for questions and consideration of the Informed Consent document. Once all patient questions&#xD;
      have been answered patients willing to be in the study will sign the Informed Consent.&#xD;
      Patients will be randomized, via standard randomization tables that provide a 1:1:1:1&#xD;
      distribution of subjects between the four groups through blocked randomization, no later than&#xD;
      the morning of surgery to either of the four treatment groups: Placebo, Preoperative IV TXA,&#xD;
      Preoperative-oral TXA only, or Full (pre-op and post-op) Oral TXA.&#xD;
&#xD;
      Sample Size Calculation: Sample size calculation determined that 151 patients per treatment&#xD;
      group (604 patients total) are required to provide an alpha of 0.05 and beta of 0.80. This&#xD;
      total of 604 patients includes a 10% drop-out rate to allow for protocol deviations.&#xD;
&#xD;
      Demographics/Patient Specifics: Age, sex, ASA score, weight, height, estimated&#xD;
      intra-operative blood loss, intra-operative fluids (crystalloid, colloid), operative time,&#xD;
      hospitalization days, BMI, pre-operative hemoglobin, hematocrit, PT/INR, PTT, and platelet&#xD;
      count.&#xD;
&#xD;
      Treatment Groups:&#xD;
&#xD;
      Group 1 PLACEBO: three 250 mg tablets of ascorbic acid 2 hours prior to incision, placebo IV&#xD;
      at time of incision intraoperatively, three 250 mg tablets of ascorbic acid given each day&#xD;
      for three days postoperatively (while in the hospital as an inpatient).&#xD;
&#xD;
      Group 2 IV TXA: three 250 mg tablets of ascorbic acid 2 hours prior to incision, 1g IV TXA&#xD;
      bolus at time of incision intraoperatively, three 250 mg tablets of ascorbic acid given each&#xD;
      day for three days postoperatively (while in the hospital as an inpatient).&#xD;
&#xD;
      Group 3 Pre-Oral TXA: three 625mg tablets of oral TXA 2 hours prior to incision, placebo IV&#xD;
      at time of incision intraoperatively, and three 250 mg tablets of ascorbic acid given each&#xD;
      day for three days postoperatively (while in the hospital as an inpatient).&#xD;
&#xD;
      Group 4 Full Oral TXA: three 625mg tablets of oral TXA 2 hours prior to incision, placebo IV&#xD;
      at time of incision intraoperatively, three 625mg tablets of oral TXA given each day for&#xD;
      three days postoperatively (while in the hospital as an inpatient).&#xD;
&#xD;
      Outcome Measurements: (Assessed during hospital stay and at routine outpatient follow-up&#xD;
      visit which occurs about 3 weeks after discharge and within 30 days of surgery) Number of&#xD;
      patients transfused (primary outcome) and units transfused Post-operative reduction in&#xD;
      hemoglobin and hematocrit&#xD;
&#xD;
      Postoperative blood loss will be determined primarily by the postoperative drop in&#xD;
      hemoglobin, which is calculated as the patient's preoperative hemoglobin minus the patient's&#xD;
      lowest postoperative hemoglobin. Secondarily, postoperative blood and hemoglobin loss will be&#xD;
      calculated as a function of patient characteristics including sex, weight, and height as well&#xD;
      as preoperative and postoperative hemoglobin balance, using the formulas previously described&#xD;
      by Nadler et al and Good et al,5,6 which have been used in prior TXA studies.1,4 Cost&#xD;
      comparison - Cost differences resulted from differences in the blood transfusion rate, length&#xD;
      of hospital stay, and management of complications as well as from the cost of the TXA itself&#xD;
      Complications - DVT/PE, return to the OR within 30 days, superficial or deep infection, and&#xD;
      cerebrovascular accident, transient ischemic attack or MI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative blood loss</measure>
    <time_frame>During hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>preoperative and postoperative hemoglobin balance</measure>
    <time_frame>During hospital stay and at routine outpatient follow-up visit which occurs about 3 weeks after discharge and within 30 days of surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">604</enrollment>
  <condition>Open Posterior Thoracolumbar Spinal Fusion Procedure</condition>
  <arm_group>
    <arm_group_label>Group 1 PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 IV TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Pre-Oral TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Full Oral TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injectable Product (1000 mg intravenous bolus)</intervention_name>
    <description>Intravenous methods to decrease blood loss</description>
    <arm_group_label>Group 2 IV TXA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C 250 MG Oral Tablet</intervention_name>
    <description>Oral method of placebo</description>
    <arm_group_label>Group 1 PLACEBO</arm_group_label>
    <arm_group_label>Group 2 IV TXA</arm_group_label>
    <arm_group_label>Group 3 Pre-Oral TXA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 650Mg Tablet</intervention_name>
    <description>Oral method of treatment group</description>
    <arm_group_label>Group 3 Pre-Oral TXA</arm_group_label>
    <arm_group_label>Group 4 Full Oral TXA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient older than 18 years old&#xD;
&#xD;
          -  Scheduled for an open posterior thoracolumbar spinal fusion procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to TXA&#xD;
&#xD;
          -  Acquired disturbances of color vision&#xD;
&#xD;
          -  Refusal of blood products&#xD;
&#xD;
          -  Pre-op use of anticoagulant therapy within five days before surgery&#xD;
&#xD;
          -  History of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Severe ischemic heart disease [New York Heart Association Class III or IV]&#xD;
&#xD;
          -  Previous myocardial infarction&#xD;
&#xD;
          -  Severe pulmonary disease&#xD;
&#xD;
          -  Renal impairment&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Patients who decline to participate&#xD;
&#xD;
          -  Intolerance or sensitivity to Vitamin C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryce Basques, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Colman, MD</last_name>
    <phone>312-432-2468</phone>
    <email>an.research@rushortho.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>6060712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Colman, MD</last_name>
      <phone>312-432-2468</phone>
      <email>an.research@rushortho.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fillingham YA, Kayupov E, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ. The James A. Rand Young Investigator's Award: A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Total Knee Arthroplasty: The Same Efficacy at Lower Cost? J Arthroplasty. 2016 Sep;31(9 Suppl):26-30. doi: 10.1016/j.arth.2016.02.081. Epub 2016 Mar 19.</citation>
    <PMID>27113948</PMID>
  </results_reference>
  <results_reference>
    <citation>Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, Reed MR. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J. 2013 Nov;95-B(11):1556-61. doi: 10.1302/0301-620X.95B11.31055.</citation>
    <PMID>24151279</PMID>
  </results_reference>
  <results_reference>
    <citation>Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 Jan;93(1):39-46. doi: 10.1302/0301-620X.93B1.24984. Review.</citation>
    <PMID>21196541</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </results_reference>
  <results_reference>
    <citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32.</citation>
    <PMID>21936146</PMID>
  </results_reference>
  <results_reference>
    <citation>Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003 May;90(5):596-9.</citation>
    <PMID>12697586</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study does not plan to share individual participant data (IPD)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

